• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 15
  • 4
  • 1
  • 1
  • 1
  • Tagged with
  • 24
  • 24
  • 24
  • 9
  • 7
  • 5
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
11

Aortic carboxypeptidase-like protein mutations and Ehlers-Danlos syndrome

Vishwanath, Neya 17 June 2019 (has links)
Ehlers-Danlos Syndrome (EDS) comprises a spectrum of heritable connective tissue disorders with varying genetic origins and clinical manifestations such as soft tissue fragility and skin hyperextensibility. There are multiple EDS subtypes, the first few of which were defined by collagen mutations. Many new EDS variants have been discovered involving mutations that do not necessarily implicate collagen biosynthesis but do involve extracellular matrix (ECM) proteins. One of these proteins, Aortic Carboxypeptidase-Like Protein (ACLP), is a large secreted protein encoded by the AEBP1 (adipocyte enhancer binding protein 1) gene. Previous research has shown that ACLP plays a vital role in binding collagen via its discoidin domain and therefore regulates connective tissue assembly. Thus far, individuals from 7 different families have been identified with different EDS-causing ACLP mutations. Some mutations are ACLP null whereas other mutations lead to expressed mutant ACLP. One of these mutations is characterized by a single-nucleotide deletion that causes the insertion of 40 amino acids in the discoidin domain of ACLP. It is therefore denoted “ACLP-Ins40”. The goal of this research was to characterize the ACLP-Ins40 protein and investigate how mutations in ACLP disrupt ECM homeostasis and cause EDS. We initially sought to determine if the ACLP-Ins40 mutation would alter ACLP’s ability to bind collagen. To achieve this goal we generated expression vectors of full length human ACLP carrying the Ins40 mutation. By western blot, it was determined that ACLP-Ins40 was not secreted from fibroblasts and was retained intracellularly. We then hypothesized that the retention of ACLP-Ins40 in the secretory pathway would induce ER stress due to misfolding. 3T3 fibroblasts were co-transfected with the ACLP-Ins40 expression vector and an XBP1u-EGFP sensor of ER stress. Immunofluorescence imaging revealed that in comparison to WT, fibroblasts expressing ACLP-Ins40 experienced ER stress with significantly increased spliced XBP1. This may then cause cell death, the improper secretion of other important ECM proteins, or defective collagen scaffolding, all which could contribute to symptoms of EDS. These studies contribute to our current understanding of how mutations in the AEBP1 gene and alterations in the ACLP protein cause EDS. This connection provides a framework for future research and for targeted interventions to treat EDS. / 2021-06-17T00:00:00Z
12

Étude des conséquences de la déficience génétique en ß1,3-galactosyltransférase 6 (ß3GalT6) sur la pathogénie d’une maladie génétique rare, le syndrome d’Ehlers-Danlos (SED) / Study of the consequences of genetic deficiency in ß1,3-galactosyltransferase 6 (?3GalT6) on the pathogenesis of a rare genetic disease, Ehlers-Danlos syndrome (SED)

Pang, Xiaomeng 16 December 2016 (has links)
Les protéoglycanes (PGs) jouent un rôle important dans de multiples processus cellulaires tels que la prolifération, la différenciation et la migration cellulaires. Les PGs sont constitués d’une protéine porteuse sur laquelle sont fixées de façon covalente des chaînes hétéropolyssacharidiques de glycosaminoglycanes (GAGs). L’initiation de la biosynthèse des GAGs sur les PGs implique une glycosyltransférase, la ß1,3-galactosyltransférase 6 (ß3GalT6) qui catalyse l’addition d’un résidu galactose sur un disaccharide accepteur (Gal-Xyl) fixé au niveau de motifs d’ancrage des GAGs sur la protéine porteuse du PG. Des mutations de la ß3GalT6 ont été récemment associées à une forme pléiotropique du syndrome d’Ehlers-Danlos (SED), un groupe hétérogène de maladies génétiques rares touchant les constituants matriciels des tissus conjonctifs. L’implication de la ß3GalT6 dans la pathogénie du SED n’est cependant pas encore connue à ce jour, point qui sera exploré au cours de ce travail de thèse. Nous avons montré que la mutation du gène B3GALT6 conduit à une diminution de la biosynthèse des GAGs matriciels et membranaires, associée à une réduction de la capacité migratoire des fibroblastes de derme humain issus de patients atteints de SED par rapport aux fibroblastes contrôle, non porteurs de l’altération génétique. Une étude “gain et perte de fonction” a montré que l’extinction du gène B3GALT6 dans des fibroblastes contrôle impacte la biosynthèse des GAGs. De façon complémentaire, la restauration de l’expression de la ß3GalT6 dans les fibroblastes des patients a eu pour conséquences une augmentation du taux de synthèse des GAGs matriciels et membranaires, associée à une augmentation significative de la capacité de migration des cellules équivalente à celle des cellules non déficientes. Les résultats obtenus nous permettent de mieux comprendre le rôle de la ß3GalT6 dans la pathogénie du SED. Ces travaux ciblant la ß3GalT6 peuvent ouvrir la perspective de proposer des stratégies thérapeutiques visant à s’opposer à la perte d’anabolisme des GAGs et au défaut de migration observés dans le SED. / Proteoglycans (PGs) play important roles in many physiological processes, including cell proliferation, differentiation and migration. PGs are composed of linear heteropolysaccharide chains, called glycosaminoglycans (GAGs), which are covalently attached to a core protein through a tetrasaccharide linkage. The addition of the third residue (galactose) of the linkage is catalyzed by ß1,3-galactosyltransferase 6 (ß3GalT6), a key glycosyltransferase in GAG initiation. Recently, mutations of ß3GalT6 have been associated to Ehlers-Danlos Syndrome (EDS), a group of rare and severe genetic connective tissue disorders. However, the role of ß3GalT6 defects in EDS pathogeny remains unknown. In my thesis, we showed that ß3GalT6 defective dermal fibroblasts of affected patients exhibited a marked reduction in GAG anabolism associated to a significant delay in wound closure compared to control cells. The ß3GalT6 gain- and loss-of-function studies demonstrated that B3GALT6 gene deletion in control fibroblasts affects the synthesis of GAGs chains. Interestingly, GAG anabolism and cell migration were restored when ß3GalT6 is overexpressed in patient fibroblasts, which could be the starting point to the development of therapeutic strategies against the loss of GAG synthesis and defect of cell migration observed in EDS. This work provides a better understanding of the crucial role of ß3GalT6 in EDS pathogeny
13

Prevalence and Predictors of Gastrointestinal Dysmotility in Patients with Hypermobile Ehlers-Danlos Syndrome: A Tertiary Care Center Experience

Alomari, Mohammad, Hitawala, Asif, Chadalavada, Pravallika, Covut, Fahrettin, Al Momani, Laith, Khazaaleh, Shrouq, Gosai, Falgun, Al Ashi, Suleiman, Abushahin, Ashraf, Schneider, Alison 29 April 2020 (has links)
Introduction Ehlers-Danlos syndrome (EDS), specifically the hypermobility type (hEDS), is associated with a variety of gastrointestinal (GI) conditions. This study aims to evaluate the prevalence of and factors associated with gut dysmotility in patients with hEDS. Methods This is a retrospective study of hEDS patients conducted at the Cleveland Clinic's Center for Personalized Genetic Healthcare between January 2007 and December 2017. Demographics, GI motility testing, endoscopic, and imaging data were extracted from the patients' charts. Results A total of 218 patients with hEDS were identified. Among them, 136 (62.3%) patients had at least one GI symptom at the time of EDS diagnosis. Motility testing was performed and reported in 42 (19.2%) patients. Out of them, five (11.9%) had esophageal dysmotility, 18 (42.8%) had gastroparesis, five (11.9%) had small bowel/colon altered transit time, and four (9.5%) had global dysmotility. In univariable analysis, patients with postural orthostatic tachycardia syndrome (POTS) [odds ratio (OR): 8.88, 95% CI: 3.69-24.9, p<0.0001], fibromyalgia (OR: 4.43, 95% CI: 2.04-10.1, p=0.0002), history of irritable bowel syndrome (OR: 5.01, 95% CI: 2.31-11.2, p<0.0001), and gastroesophageal reflux disease (OR: 3.33, 95% CI: 1.55-7.44, p=0.002) were more likely to be diagnosed with GI dysmotility. On multivariable analysis, only POTS (OR: 5.74, 95% CI: 2.25-16.7, p=0.0005) was significantly associated with an increased likelihood of GI dysmotility. Conclusions This study suggests that GI symptoms are relatively common among patients with hEDS. Of the patients tested for dysmotility, 76.2% were found to have some form of dysmotility. POTS was found to be an independent predictive factor for GI dysmotility.
14

Examining Differences in Symptoms in Individuals with Hypermobile Ehlers-Danlos Syndome in Relation to Puberty

Heraty, Katelyn M. 17 October 2014 (has links)
No description available.
15

Quality of Life, Coping, Support Systems and Chronic Pain in Ehlers Danlos Syndrome

Fox, Shawna S. 24 October 2014 (has links)
No description available.
16

Joint Hypermobility Syndrome: A Common Clinical Disorder Associated with Migraine Headache in Women

Bendik, Elise 30 September 2010 (has links)
No description available.
17

The Association of Functional Disability and Pain Catastrophizing with Healthcare Utilization among Individuals with Ehlers-Danlos Syndrome Hypermobility Type (EDS-HT)

Barfiwala, Kanchi N. 06 June 2016 (has links)
No description available.
18

Living with Ehlers-Danlos syndrome /

Berglund, Britta, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 4 uppsatser.
19

Aspects physiopathologiques du syndrome d'Ehlers-Danlos vasculaire / Physiopathologic aspects of the vascular Ehlers–Danlos syndrome

Mirault, Tristan 06 November 2015 (has links)
Le syndrome d'Ehlers-Danlos (SEDv) est une maladie artérielle génétique autosomique dominante, affectant le collagène de type III au sein de la matrice extracellulaire de la paroi artérielle notamment. Les patients atteints de SEDv ont une prédisposition aux ruptures artérielles, digestives et utérines qui font toute la sévérité de cette maladie. Les mutations du gène COL3A1 codant pour le collagène de type III sont le plus souvent des mutations hétérozygotes faux-sens, responsables de la substitution d'une glycine par un autre acide aminé, affectant la structure en triple hélice du collagène de type III. Des variants d'un site d'épissage, des insertions-délétions sont également rencontrées, et plus rarement des mutations faux-sens n'affectant pas une glycine, ou des mutations responsables d'haploinsuffisance. Les mutations du COL3A1 sont presque exclusivement privées, et une corrélation entre le phénotype observé et les mutations retrouvées n'a jamais été mise en évidence. Nous avons rapporté l'expérience du centre de référence français du SEDv sur 215 patients, et retrouvé une sévérité de la maladie plus importante chez ceux avec une substitution glycine, ou une insertion/délétion du cadre de lecture dans région de la triple hélice comparativement aux autres génotypes: variants responsables d'haploinsuffisance, variants faux-sens n'affectant pas une glycine, ou les altérations des extrémités N ou C-terminales. Par ailleurs, le phénotype de ces 3 derniers groupes de génotype ne rassemblait pas l'ensemble des symptômes habituellement décrits dans le SEDv et notamment pas de complication digestive. Afin de mieux comprendre l'altération des propriétés biomécaniques de la paroi artérielle des patients atteints de SEDv nous avons utilisé une nouvelle technologie ultrasonore, ultrafastécho, permettant de visualiser et mesurer la vitesse de l'onde de pouls (VOP) localement au niveau carotidien et tout au long du cycle cardiaque. La VOP est un marqueur de rigidité artérielle bien étudié dans l'athérosclérose, et connu pour être un facteur indépendant de mortalité cardiovasculaire. Nous avons établi des valeurs normales des paramètres de l'ultrafastécho chez 102 volontaires sains et analysés 37 patients avec SEDv. Cette étude n'a pas retrouvé de différence de la VOP, donc de rigidité artérielle, en début de systole. En revanche, au cours du cycle cardiaque on a pu observer une moindre rigidification de la paroi artérielle avec l'augmentation de la pression artérielle chez les patients SEDv. Nous avons poursuivi nos explorations par ultrafastécho sur un modèle murin haploinsuffisant pour le collagène de type III (souris Col3a1 hétérozygote) et retrouvé le même profil de réponse. En effet une moindre augmentation de la rigidité artérielle alors que la pression artérielle était augmentée par perfusion de vasopresseur était constatée chez les souris col3a1 hétérozygotes comparativement aux souris sauvages. En conclusion, l'altération du collagène de type III dans le SEDv affecte les propriétés biomécaniques de la paroi artérielle des patients, avec notamment une moindre rigidification lors de l'augmentation de la pression artérielle. Nos travaux ont permis d’affiner la physiopathologie du SEDv, de préciser le phénotype vasculaire par une nouvelle mesure de la VOP et ouvrent des pistes de recherche thérapeutiques d'un traitement augmentant la rigidité artérielle afin de tenter de réduire les risques de ruptures artérielles. / Vascular Elhers-Danlos syndrome (vEDS) is an autosomal dominant genetic vascular disease, affecting the collagen type III, a component in the extracellular matrix of the arterial wall. Patients with vEDS are prone to arterial, intestine or uterine ruptures, which explain the severity of the disease. Mutations in COL3A1, gene encoding for collagen type III are usually heterozygous missense mutations responsible for the substitution of a glycine amino acid for another, which affects the triple helical conformational structure of the collagen type III. Variants of a splice site, deletions/insertions, are also encountered, and more rarely missense mutations not affecting a glycine residue, or alterations responsible for haploinsufficiency. The COL3A1 mutations are almost exclusively private, and a genotype/phenotype correlation has not been clearly studied. We reported the experience of the French reference center for vEDS of 215 patients and found a greater severity of the disease in those with a glycine substitution, or in frame insertion / deletion within the triple helix domain than in other genotypes: responsible variants of haploinsufficiency, missense variants not affecting glycine, or alteration of the N- or C-terminal ends. Furthermore, the phenotype of these last three genotype groups did not combine the complete phenotype described in vEDS especially no gastrointestinal complication. To better understand the alteration of the biomechanical properties of the arterial wall of patients with vEDS we used a new ultrasound technology, ultrafastecho, to visualize and measure the pulse wave velocity (PWV) locally on carotids, over the cardiac cycle. The PWV is a marker of arterial stiffness studied in atherosclerosis, and well known to be an independent risk factor for cardiovascular mortality. We have established normal values ultrafastecho parameters in 102 healthy volunteers and 37 patients with vEDS. This study found no difference in PWV, thus arterial stiffness, in early systole cardiac at diastolic blood pressure. However, in patients with vEDS, weaker stiffening of the arterial wall was observed when blood pressure increases during the cardiac cycle. We continued our explorations by ultrafastecho on a mouse model of vEDS, haploinsufficient for the collagen type III (Col3a1 heterozygous mice). We figured out that Col3a1 heterozygous mice presented the same response profile. Indeed a smaller increase in arterial stiffness while blood pressure was increasing secondary to vasopressor infusion was revealed in the mice compared to the wild mice. In conclusion, alterations of collagen type III in the vEDS affect the biomechanical properties of the arterial wall of the patient, through lower stiffening during the increase of blood pressure over the cardiac cycle. This provides a therapeutic approach for targeting treatment increasing arterial stiffness in vEDS in order to reduce the risk of arterial rupture.
20

Upplevelser av bemötande vid Ehlers-Danlos syndrom

Jonsson, Carolina January 2018 (has links)
Research shows that individuals who had negative encounters in healthcare had significantly less contact with healthcare. Ehlers-Danlos syndrome is a challenge to diagnose and treat. Studies have shown that individuals with Ehlers-Danlos syndrome for these reasons avoid healthcare with the risk of worsening of their own health, something that can depend on negative encounters. The purpose of this study is to give a descriptive overview of how people with Ehlers-Danlos syndrome experience encounters in healthcare. The research questions are “Do individuals with Ehlers-Danlos syndrome experience good access to healthcare?” and “How do individuals with Ehlers-Danlos syndrome experience encounters in healthcare?” An electronic survey was distributed through social media via Ehlers-Danlos national association in Sweden. The number of respondents was 521 of an estimated number of 814 adult individuals with Ehlers-Danlos syndrome in Sweden. The results show that 477 individuals have experienced offensive or reducing behavior from treating physicians. The majority report bad encounters and low availability in healthcare. The result also shows that it takes approximately 15,28 years to diagnose the condition. / Forskning har visat att individer som upplever negativt bemötande inom vården har mindre vårdkontakt. Ehlers-Danlos syndrom är en utmaning för vården att diagnostisera och behandla vilket en studie visar fört med sig att patienterna undviker vården med sämre hälsa som följd, något som kan bero på erfarenheter av negativt bemötande. Syftet med denna studie är att ge en beskrivning av hur individer med Ehlers-Danlos syndrom upplever bemötande inom primärvården. Två frågeställningar formulerades: Upplever individer med Ehlers-Danlos syndrom god tillgänglighet av vård? och Hur upplever individer med Ehlers-Danlos syndrom bemötande inom primärvården?  En elektronisk enkät skickades ut via sociala medier till patientgrupper med Ehlers-Danlos syndrom där Ehlers-Danlos Riksförbund bistod i distribueringen. Antalet som svarade var 521 stycken av ett estimerat antal om 814 vuxna individer med Ehlers-Danlos syndrom i Sverige. Resultatet visar att 477 individer någon gång upplevt kränkande eller förminskande bemötande av behandlande läkare. Majoriteten rapporterar dåligt bemötande och låg tillgänglighet av tider till primärvården. Resultatet visar dessutom att genomsnittstiden för diagnos ligger på 15,28 år.

Page generated in 0.0783 seconds